KXAN

BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture

VANCOUVER, BC and MADISON, Wis., April 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly ...
Nasdaq

BioVaxys to Present at the Life Sciences Investor Forum on September 19th

VANCOUVER, BC, Sept. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of ...
Seeking Alpha

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase ...
Business Insider

BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program

VANCOUVER, BC, March 18, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications ...
Morningstar

BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit

BioVaxys Chief Medical Officer David Berd, MD, will present new data from recent in vivo studies of DPX conducted by Pramrod K. Srivastava, Ph.D., M.D., Professor, Department of Immunology, Director, ...
Business Insider

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug ...
Morningstar

BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

VANCOUVER, BC and MADISON, Wis., Oct. 14, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that ...
PR Newswire

BIOVAXYS ANNOUNCES PRIVATE PLACEMENT OFFERING

VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it intends to complete a non-brokered private ...
Troy Record

BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T

VANCOUVER, BC, March 31, 2021 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) (“BioVaxys”), the world leader in haptenized antigen vaccines for antiviral and cancer applications, ...
Nasdaq

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has ...
Seeking Alpha

BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture

Submission Process Underway for Regulatory Approval of SpayVac in Feral Horses and Free-Ranging Deer Populations VANCOUVER, BC and MADISON, Wis., April 22, 2025 /PRNewswire/ -- BioVaxys Technology ...